Loading...
OTCMSPHRY
Market cap28mUSD
Jan 08, Last price  
0.72USD
1Q
21.48%
Jan 2017
-86.31%
Name

Starpharma Holdings Ltd

Chart & Performance

D1W1MN
OTCM:SPHRY chart
P/E
—
P/S
58.57
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.07%
Rev. gr., 5y
24.96%
Revenues
8m
+182.03%
2,049,298500863,8541,412,0002,019,0001,404,0001,144,000925,00020,0001,253,0001,697,0004,574,0003,647,0004,957,0002,720,0006,033,0001,798,0004,682,0002,939,0008,289,000
Net income
-8m
L-47.79%
-7,585,992-7,522,789-7,244,996-7,491,000-4,127,000-6,378,000-8,930,000-13,658,000-5,229,000-14,635,000-18,950,000-21,292,000-15,217,000-10,285,000-14,254,000-14,678,000-19,732,000-16,154,000-15,638,000-8,164,999
CFO
-7m
L-48.44%
-5,808,589-7,489,948-3,380,194-5,352,000-4,029,000-3,630,000-6,476,000-9,770,000-9,795,000-9,813,000-13,615,000-17,811,000-16,955,000-10,201,000-10,344,000-10,776,000-14,808,000-13,162,000-13,533,000-6,977,000
Earnings
Feb 26, 2025

Profile

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
URL
https://www.starpharma.com/
IPO date
Sep 28, 2000
Employees
45
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
8,289
182.03%
2,939
-37.23%
4,682
160.40%
Cost of revenue
19,784
27,612
28,577
Unusual Expense (Income)
NOPBT
(11,495)
(24,673)
(23,895)
NOPBT Margin
Operating Taxes
(5,527)
(7,631)
(7,261)
Tax Rate
NOPAT
(5,968)
(17,042)
(16,634)
Net income
(8,165)
-47.79%
(15,638)
-3.19%
(16,154)
-18.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,571
5,522
695
Long-term debt
4,710
5,500
7,494
Deferred revenue
Other long-term liabilities
79
48
3,551
Net debt
(17,079)
(24,158)
(41,729)
Cash flow
Cash from operating activities
(6,977)
(13,533)
(13,162)
CAPEX
(89)
(621)
(837)
Cash from investing activities
(89)
(610)
(836)
Cash from financing activities
(4,747)
(695)
3,228
FCF
(6,376)
(18,276)
(20,354)
Balance
Cash
23,360
35,180
49,918
Long term investments
Excess cash
22,946
35,033
49,684
Stockholders' equity
28,116
34,815
48,393
Invested Capital
8,777
8,320
8,246
ROIC
ROCE
EV
Common stock shares outstanding
411,433
409,035
406,900
Price
0.10
-69.35%
0.31
-58.11%
0.74
-50.50%
Market cap
39,086
-69.18%
126,801
-57.89%
301,106
-49.25%
EV
22,007
102,643
259,377
EBITDA
(10,380)
(23,480)
(22,816)
EV/EBITDA
Interest
Interest/NOPBT